3/6/2023 8:07:10 AM
Rallybio Corp. Q4 Net Loss/shr $0.46 Vs. Loss/shr $0.42 Last Year
2/27/2023 7:27:32 AM
EyePoint, Rallybio Collaborate For Rallybio’s Inhibitor Of Complement C5 And EyePoint’s Proprietary Durasert Technology
12/1/2022 7:08:19 AM
AbCellera, Rallybio To Discover, Develop, And Commercialize Novel Antibody-Based Therapeutics For Rare Diseases
11/11/2022 12:04:29 AM
Rallybio Announces Pricing Public Offering Of 5 Mln Shares At $6/Shr
11/7/2022 8:07:33 AM
Rallybio Corp. Q3 Net Loss/shr $0.60 Vs. Loss/shr $0.37 Last Year
9/28/2022 8:09:08 AM
Rallybio Announces Positive Results For RLYB212 For Prevention Of Fetal And Neonatal Alloimmune Thrombocytopenia
8/8/2022 8:07:41 AM
Rallybio Corp. Q2 Net Loss/shr $0.57 Vs. Loss/shr $0.49 Last Year
5/10/2022 8:18:12 AM
Rallybio Q1 Net Loss $14.5 Mln $0.48/Shr Vs Loss Of $13.3 Mln Or $0.60/Shr Last Year
3/15/2022 8:07:55 AM
Rallybio Q4 Net Loss $12.4 Mln Or $0.42/Shr Vs Loss Of $10.5 Mln Or $0.47/Shr Last Year
11/10/2021 7:19:56 AM
Rallybio Q3 Net Loss $10.2 Mln Or $0.37/shr Vs. Loss $7.2 Mln Or $0.32/shr Prior Year